ARA-290
ResearchA non-erythropoietic analog of erythropoietin researched for neuropathic pain, nerve repair, and metabolic benefits in type 2 diabetes research.
NeuroprotectionPain ResearchMetabolic Health
Half Life
Unknown
Time to Results
Weeks to months
Administration
SubQ injection
🐾 Griffin's Research Scorecard
Research Strength
Human Data
Animal Data
Long-Term Data
Beginner Friendly
Storage Difficulty
Injection FrequencyDaily
Cost$$$
🐾 Griffin Says...
ARA-290 started as a safer version of erythropoietin (EPO) without the blood-thickening risk. Researchers discovered it has remarkable nerve-repairing properties. Particularly interesting for sarcoidosis-related neuropathy research.
Benefits
- Neuropathic pain reduction
- Nerve repair
- Anti-inflammatory
- Potential metabolic benefits
- Small fiber neuropathy research
Best For
- Nerve pain research
- Neuropathy research
- Sarcoidosis research
Body Systems
Nervous SystemImmuneMetabolic
Mechanisms of Action
- Binds innate repair receptor (IRR)
- Promotes tissue protection and repair
- Anti-inflammatory signaling
- No effect on red blood cell production
Side Effects
| Effect | Frequency | Severity |
|---|---|---|
| Minimal reported in trials | Rare | Mild |
Contraindications
Limited data available
Peptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.
Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾
Open Calculator